CatalystMarker
← board

SYBX

distress 1/10 · well-funded / low risk
$0.71+1%today-61% from 52w high
synlogictx.com1 employeesWinchester, MABiotechnology
Revenue
pre-revenue
Liquidity
$14M
Runway
4.3 yrs
Shares 1y
0%

Price & events

+24.5% over 6M
$0.56$0.68$0.79Jan 26Apr 26Jul 26353k
CatalystRating changeDilutionFinancingdashed = today
+0.9%
1D
+1.4%
1W
-1.3%
1M
+13.4%
3M
+24.5%
6M
-55.6%
1Y
-56.6%
2Y
-98.5%
5Y
-97.8%
All

Overview

Market Cap
$8.32M
Volume
4.30K
52 Week Range
$0.56 – $1.83
Total Shares
11.70M
Float Shares
6.40M
Short %
0.20%
% Held by Insiders
16.39%
% Held by Institutions
35.28%
RVOL
0.36x
Beta
0.54

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 11,696,641 · 0 offerings/1y · 0 PIPEs
  • 2025-08-20EFFECTshelf_effective
  • 2025-08-15S-3/Ashelf_registration
  • 2025-08-08S-3shelf_registration
  • 2024-11-14SC 13G/Astrategic_stake
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Recent news

  • none

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.